Samsung Bioepis signs Teva biosimilar deal worth up to $420 million
TEVA•Samsung Bioepis signed a deal with Teva worth up to $420 million. Teva will sell two FDA-approved biosimilars in the U.S., while Samsung Bioepis handles development, manufacturing and supply.
1. Deal terms
The agreement, signed November 2, 2026, covers Teva’s U.S. sales of SB2, a Remicade biosimilar, and SB4, an Enbrel biosimilar. Samsung Bioepis will handle development, manufacturing and supply, and the companies will share commercialization profits. Payments include up to $75 million upfront, up to $75 million in launch milestones and up to $270 million in sales milestones, subject to contractual targets.
